Home › Activist investors › Mangless Daniel John
Dissident not on the roster. Positions and campaigns from Mangless Daniel John’s SEC filings. Updated November 20, 2026.
No active campaign by this definition (see How to read this).
No current position by this definition.
Campaigns are compiled from SEC filings (13D, proxy contest filings and settlement 8-Ks); campaigns run without SEC filings, e.g. by public letter below the 5% threshold, may not appear.
| Company | Outcome or last status | Date | First filing | Highest stage | Filings | Meeting / votes |
|---|---|---|---|---|---|---|
| Zevra Therapeutics, Inc.Board seats | Contested vote held — 0 of 1 of the activist's nominees elected | May 29, 2025 | Mar 3, 2023 | Proxy contest filed | latest (11) | how managers voted |
Fund votes come from Form N-PX filings, which this site holds from July 1, 2023 (meetings through June 30, 2026; later meetings appear when the managers file their next N-PX); earlier contests and campaigns that settled before a vote are listed under the activist’s campaigns.
Contested director elections at which Mangless Daniel John had nominees on the ballot, from the managers’ N-PX vote reports and the company’s Form 8-K (Item 5.07) results. A manager “backed” a side when most of its funds’ votes on that side’s nominees were FOR; with a universal proxy card a fund can vote for nominees of both sides, so the counts are shown too.
| Manager | Backed the activist | Zevra Therapeutic… 2025 |
|---|---|---|
| Vanguard | 0 of 1 (0%) | Company |
| BlackRock | 0 of 1 (0%) | Company |
| Fidelity | 0 of 1 (0%) | Company |
| Charles Schwab | 0 of 1 (0%) | Company |
| Pacific Life | 0 of 1 (0%) | Company |
| Equitable | 0 of 1 (0%) | Company |
| TIAA | 0 of 1 (0%) | Company |
| QUANTITATIVE MASTER SERIES LLC | 0 of 1 (0%) | Company |
| Lincoln Financial | 0 of 1 (0%) | Company |
| State Street | 0 of 1 (0%) | Company |
| Global X | 0 of 1 (0%) | Company |
| AIG/SunAmerica | 0 of 1 (0%) | Company |
| Northern Trust | 0 of 1 (0%) | Company |
| ProShares | 0 of 1 (0%) | Company |
| John Hancock | 0 of 1 (0%) | Company |
| Bridge Builder Trust | 0 of 1 (0%) | Company |
| Brighthouse | 0 of 1 (0%) | Split |
| SEI | 0 of 1 (0%) | Company |
| Nationwide | 0 of 1 (0%) | Company |
| Guardian Variable Products Trust | 0 of 1 (0%) | Company |
— = no N-PX votes on the contested director elections found for that manager.
Result: Form 8-K, Item 5.07. Activist’s nominees: Arthur C. Regan (not elected (8-k tally)). Company’s nominees: Wendy Dixon, Ph.D. (elected (8-k tally)); Tamara A. Favorito (elected (8-k tally)).
| Manager | Stance | FOR the activist’s nominees | Avg. shares FOR each activist nominee | FOR the company’s nominees |
|---|---|---|---|---|
| Vanguard | Backed the company's nominees | 0 of 9 fund votes | 0 | 18 of 18 fund votes |
| BlackRock | Backed the company's nominees | 0 of 11 fund votes | 0 | 22 of 22 fund votes |
| Fidelity | Backed the company's nominees | 0 of 19 fund votes | 0 | 38 of 38 fund votes |
| Charles Schwab | Backed the company's nominees | 0 of 2 fund votes | 0 | 4 of 4 fund votes |
| Pacific Life | Backed the company's nominees | 0 of 5 fund votes | 0 | 10 of 10 fund votes |
| Equitable | Backed the company's nominees | 0 of 8 fund votes | 0 | 16 of 16 fund votes |
| TIAA | Backed the company's nominees | 0 of 5 fund votes | 0 | 10 of 10 fund votes |
| QUANTITATIVE MASTER SERIES LLC | Backed the company's nominees | 0 of 1 fund votes | 0 | 2 of 2 fund votes |
| Lincoln Financial | Backed the company's nominees | 0 of 1 fund votes | 0 | 2 of 2 fund votes |
| State Street | Backed the company's nominees | 0 of 4 fund votes | 0 | 8 of 8 fund votes |
| Global X | Backed the company's nominees | 0 of 1 fund votes | 0 | 2 of 2 fund votes |
| AIG/SunAmerica | Backed the company's nominees | 0 of 2 fund votes | 0 | 4 of 4 fund votes |
| Northern Trust | Backed the company's nominees | 0 of 1 fund votes | 0 | 2 of 2 fund votes |
| ProShares | Backed the company's nominees | 0 of 11 fund votes | 0 | 22 of 22 fund votes |
| John Hancock | Backed the company's nominees | 0 of 3 fund votes | 0 | 6 of 6 fund votes |
| Bridge Builder Trust | Backed the company's nominees | 0 of 2 fund votes | 0 | 4 of 4 fund votes |
| Brighthouse | Split | 0 of 2 fund votes | 0 | 2 of 4 fund votes |
| SEI | Backed the company's nominees | 0 of 1 fund votes | 0 | 2 of 2 fund votes |
| Nationwide | Backed the company's nominees | 0 of 2 fund votes | 0 | 4 of 4 fund votes |
| Guardian Variable Products Trust | Backed the company's nominees | 0 of 1 fund votes | 0 | 2 of 2 fund votes |
| DWS | Backed the company's nominees | 0 of 1 fund votes | 0 | 2 of 2 fund votes |
| Goldman Sachs | Backed the company's nominees | 0 of 1 fund votes | 0 | 2 of 2 fund votes |
| Victory Capital | Backed the company's nominees | 0 of 1 fund votes | 0 | 2 of 2 fund votes |
| Voya | Backed the company's nominees | 0 of 2 fund votes | 0 | 4 of 4 fund votes |
| Direxion Shares ETF Trust | Backed the company's nominees | 0 of 1 fund votes | 0 | 2 of 2 fund votes |
| T. Rowe Price | Backed the company's nominees | 0 of 1 fund votes | 0 | 2 of 2 fund votes |
| AQR | Backed the company's nominees | 0 of 1 fund votes | 0 | 2 of 2 fund votes |
| Calvert | Backed the company's nominees | 0 of 1 fund votes | 0 | 2 of 2 fund votes |
| Dimensional | Backed the company's nominees | 0 of 1 fund votes | 0 | 2 of 2 fund votes |
| Columbia Threadneedle | Backed the company's nominees | 0 of 1 fund votes | 0 | 2 of 2 fund votes |
| PENN SERIES FUNDS INC | Backed the company's nominees | 0 of 1 fund votes | 0 | 2 of 2 fund votes |
| Brinker Capital Destinations Trust | Backed the company's nominees | 0 of 1 fund votes | 0 | 2 of 2 fund votes |
| Guggenheim | Backed the company's nominees | 0 of 4 fund votes | 0 | 8 of 8 fund votes |
| Advisors' Inner Circle Fund III | Backed the company's nominees | 0 of 1 fund votes | 0 | 2 of 2 fund votes |
Source: N-PX reports filed by 34 managers for the meeting of May 29, 2025; a nominee’s side is read from how most filers labelled the ballot item (two or more filers, 70% agreeing).
How each campaign on record ended, as read from the filings: settlements disclosed in the company’s 8-K or the investor’s 13D, contested votes (8-K Item 5.07), withdrawals and 13D amendments below 5%.
| Company | Outcome | Detail | Date | First filing |
|---|---|---|---|---|
| Zevra Therapeutics, Inc. | Contest vote: nominees not elected | 0 of 1 of the activist's nominees elected | May 29, 2025 | Mar 3, 2023 |
The change in the company’s closing share price from the first trading day on or before the investor’s first Schedule 13D to the latest close, and to 6 and 12 months after it, beside the S&P 500 (SPY) over the same dates. This is a price change after a filing date: it is not attributed to the investor, and it is not the investor’s return. Coverage: 0 of 0 13D positions have prices (the site’s daily price history starts November 10, 2025, and covers only listed tickers it tracks).